R&D internationalisation patterns in the global pharmaceutical industry: evidence from a network analytic perspective

References

• Breschi, S., and L. Cusmano. 2004. “Unveiling the Texture of a European Research Area: Emergence of Oligarchic Networks Under EU Framework Programmes.” International Journal of Technology Management 27 (8): 747–772. doi: 10.1504/IJTM.2004.004992
   Web of Science ®Google Scholar
• Cantwell, J., and R. Mudambi. 2005. “MNE Competence-creating Subsidiary Mandates.” Strategic Management Journal 26 (12): 1109–1128. doi: 10.1002/smj.497
   Web of Science ®Google Scholar
• Chesbrough, H. W. 2003. Open Innovation: The New Imperative for Creating and Profiting from Technology. Boston, MA: Harvard Business School Press.
   Google Scholar
• Comanor, W. S., and F. M. Scherer. 2013. “Mergers and Innovation in the Pharmaceutical Industry.” Journal of Health Economics 32 (1): 106–113. doi: 10.1016/j.jhealeco.2012.09.006
   PubMed Web of Science ®Google Scholar
• Dachs, B. 2014. “Internationalisation of R&D: A Brief Survey of the literature.” In The Internationalisation of Business R&D, edited by B. Dachs, R. Stehrer, and G. Zahradnik, 5–26. Cheltenham: Edward Elgar.
   Google Scholar
• Danzon, P. M. 2000. “The Pharmaceutical Industry.” In The Encyclopedia of Law and Economics, edited by B. Bouckaert, and G. de Gees, 1055–1091. Cheltenham: Edward Elgar.
   Google Scholar
• Danzon, P. M. 2006. “Economics of the Pharmaceutical Industry.” NBER Reporter Online, Fall: 14–17. http://www.nber.org/reporter/fall06/danzon.html.
   Google Scholar
• DiMasi, J. A., L. Feldman, A. Seckler, and A. Wilson. 2010. “Trends in Risks Associated with New Drug Development: Success Rates for Investigational Drugs.” Clinical Pharmacology & Therapeutics 87 (3): 272–277. doi: 10.1038/clpt.2009.295
   PubMed Web of Science ®Google Scholar
• Dunning, J., and R. Narula. 1995. “The R&D Activities of Foreign Firms in the United States.” International Studies of Management & Organization 25 (1–2): 39–72.
   Google Scholar
• Erdős, P., and A. Rényi. 1959. “On Random Graphs I.” Publicationes Mathematicae 6: 290–297.
   Google Scholar
• Friedman, Y. 2010. “Location of Pharmaceutical Innovation: 2000–2009.” Nature Review Drug Discovery 9 (11): 835–836. doi: 10.1038/nrd3298
   PubMed Web of Science ®Google Scholar
• Hall, B. A. 2010. The Internationalization of R&D. Berkeley: University of California. http://elsa.berkeley.edu/users/bhhall/papers/BHH10_RND_international_August.pdfhttp://elsa.berkeley.edu/users/bhhall/papers/BHH10_RND_international_August.pdf.
   Google Scholar
• Hatzichronoglou, T. 1997. “Revision of the HighTechnology Sector and Product Classification.” OECD Science, Technology and Industry Working Papers, 1997/02. Paris: OECD.
   Google Scholar
• Hatzichronoglou, T. 2008. The Location of Investment of Multinationals Linked to Innovation. Paris: OECD.
   Google Scholar
• Heller-Schuh, B., M. J. Barber, L. Henriques, M. Paier, D. Pontikakis, T. Scherngell, G. A. Veltri, and M. Weber. 2011. Analysis of Networks in European Framework Programmes (1984–2006). Institute for Prospective and Technological Studies, Joint Research Centre.
   Google Scholar
• Higham, D. J., and M. Kibble. 2004. “A Unified View of Spectral Clustering.” Mathematics Research Report 2, University of Strathclyde.
   Google Scholar
• Hu, Y., T. Scherngell, S.-N. Man, and Y. Wang. 2013. “Is the United States Still Dominant in the Global Pharmaceutical Innovation Network?” PLOS One 8 (11): e77247. doi: 10.1371/journal.pone.0077247
   PubMedGoogle Scholar
• Hughes, B. 2010. “Evolving R&D for Emerging Markets.” Nature Reviews Drug Discovery 9: 417–420. doi: 10.1038/nrd3204
   PubMed Web of Science ®Google Scholar
• Kaitin, K. I. 2010. “Deconstructing the Drug Development Process: The New Face of Innovation.” Clinical Pharmacology & Therapeutics 87 (3): 356–361. doi: 10.1038/clpt.2009.293
   PubMed Web of Science ®Google Scholar
• Knoke, D., and S. Young. 2008. Social Network Analysis. Los Angeles, CA: Sage.
   Google Scholar
• Kuemmerle, W. 1999. “Foreign Direct Investment in Industrial Research in the Pharmaceutical and Electronics Industries – Results from a Survey of Multinational Firms.” Research Policy 28 (2): 179–193. doi: 10.1016/S0048-7333(98)00110-3
   Web of Science ®Google Scholar
• Lakkis, M. M. 2010. “Global and Regional Drug Regulatory Harmonization Initiatives.” Drug Information Journal 44 (3): 289–297.
   Web of Science ®Google Scholar
• Ledford, H. 2013. “US Fiscal Deal Leaves Science Vulnerable.” Nature 493: 13. doi: 10.1038/493013a
   PubMed Web of Science ®Google Scholar
• Leitner, K-H., J. Butler, G. Cerulli, T. Dunnewijk, F. Kampik, A. Kasztler, H. Meijers, et al. 2011. “Analysis of the Evolution of the Costs of Research – Trends, Drivers and Impacts.” Final Report, Study Commissioned by DG Research & Innovation, Contract: RTD/B2/2009/COST-2009-01, September.
   Google Scholar
• Leitner, S., B. Dachs, and R. Stehrer. 2013. “Determinants of International R&D Activities. Evidence from a Gravity Model.” In The Geography of Networks and R&D Collaborations Advances in Spatial Science, edited by T. Scherngell, 175–200. Berlin, Heidelberg: Springer.
   Google Scholar
• Narula, R., and A. Zanfei. 2005. “Globalisation of Innovation: The Role of Multinational Enterprises.” In The Oxford Handbook of Innovation, edited by J. Fagerberg, D. C. Movery, and R. R. Nelson, 318–348. Oxford: Oxford University Press.
   Google Scholar
• Newman, M. 2010. Networks: An Introduction. Oxford: Oxford University Press.
   Google Scholar
• OECD. 2008. Recent Trends in the Internationalisation of R&D in the Enterprise Sector, DSTI/EAS/IND/SWP 20061/Final. Paris: OECD.
   Google Scholar
• OECD. 2010. Measuring Globalisation: OECD Economic Globalisation Indicators 2010. Paris: OECD.
   Google Scholar
• Rafols, I., M. M. Hopkins, J. Hoekman, J. Siepel, A. O'Hare, A. Perianes-Rodríguez, and P. Nightingale. 2014. “Big Pharma, Little Science? A Bibliometric Perspective on Big Pharma's R&D Decline.” Technological Forecasting and Social Change 81: 22–38. doi: 10.1016/j.techfore.2012.06.007
   Web of Science ®Google Scholar
• Ramirez, P. 2006. “The Globalisation of Research in the Pharmaceutical Industry: A Case of Uneven Development.” Technology Analysis & Strategic Management 18 (2): 143–167. doi: 10.1080/09537320600624006
   Web of Science ®Google Scholar
• Saillot, J., and M. Paxton. 2009. “Industry Efforts on Simultaneous Global Development.” Drug Information Journal 43 (4): 339–347.
   Google Scholar
• Scherngell, T. 2013. “The Structure of Cross-country R&D Expenditure: A Social Network Analysis Perspective.” In The Internationalisation of Business R&D, edited by B. Dachs, R. Stehrer, and G. Zahradnik, 91–104. Cheltenham: Edward Elgar.
   Google Scholar
• Thiers, F. A., A. J. Sinskey, and E. R. Berndt. 2008. “Trends in the Globalization of Clinical Trials.” Nature Reviews Drug Discovery 7 (1): 13–14. doi: 10.1038/nrd2441
   Web of Science ®Google Scholar
• Tijssen, R. 2009. “Internationalisation of Pharmaceutical R&D: How Globalised are Europe's Largest Multinational Companies?” Technology Analysis & Strategic Management 21 (7): 859–879. doi: 10.1080/09537320903182330
   Web of Science ®Google Scholar
• Von Zedtwitz, M., and O. Gassmann. 2002. “Market versus Technology Drive in R&D Internationalization: Four Different Patterns of Managing Research and Development.” Research Policy 31 (4): 569–588. doi: 10.1016/S0048-7333(01)00125-1
   Web of Science ®Google Scholar
• Wasserman, S., and K. Faust. 1994. Social Network Analysis: Methods and Applications. Cambridge: Cambridge University Press.
   Google Scholar
• Watts, D. J., and S. H. Strogatz. 1998. “Collective Dynamics of ‘Small-world’ Networks.” Nature 393: 409–410. doi: 10.1038/30918
   PubMed Web of Science ®Google Scholar
• Zahradnik, G. 2014. “The Sectoral Perspective.” In The Internationalisation of Business R&D, edited by B. Dachs, R. Stehrer, and G. Zahradnik, 71–80. Cheltenham: Edward Elgar.
   Google Scholar